论文部分内容阅读
目的:探讨血小板糖蛋白11b/111a受体拮抗剂与低剂量溶栓剂联合治疗老年人急性ST段抬高型心肌心肌梗死(STEMI)的疗效、转归及预后。方法:70岁以上老年STEMI患者25例,70岁以下者25例,应用阿昔单抗0.25mg/kg静注,替奈普酶(TNK-tPA)15～25mg治疗。分析2组治疗效果及预后情况。结果:老年组预后良好者21例(84%),死亡4例(16%)。对照组25例,预后良好者22例(88%),死亡3例(12%),差异无统计学意义(p>0.05)。结论:阿昔单抗合用低剂量替奈普酶治疗将对70岁以上老年(STEMI)获益。
Objective: To investigate the efficacy, outcome and prognosis of platelet glycoprotein 11b / 111a receptor antagonist in combination with low-dose thrombolytic therapy in elderly patients with acute ST-segment elevation myocardial infarction (STEMI). Methods: 25 elderly patients with STEMI over 70 years old and 25 under 70 years old were treated with 0.25 mg / kg abciximab and 15 ~ 25 mg tenecteplase (TNK-tPA). Analysis of two groups of treatment and prognosis. Results: In the elderly group, 21 patients (84%) had good prognosis and 4 patients died (16%). There were 25 cases in the control group, 22 cases (88%) with good prognosis and 3 cases (12%) died, the difference was not statistically significant (p> 0.05). CONCLUSION: Abciximab combined with low-dose tenecteplase will benefit STEMI in patients over 70 years of age.